Innate Pharma SA

General Information
Business:

(Note: Not an IPO: Our ordinary shares are listed on Euronext Paris under the symbol “IPH.” On October 3, 2019, the last reported sale price of our ordinary shares on Euronext Paris was €6.85 per ordinary share, equivalent to a price of $7.50 per ADS, assuming an exchange rate of €1.00 = $1.0951, the exchange rate on October 3, 2019.)

We are a biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have extensive experience in research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 208
Founded: 1999
Contact Information
Address 117, Avenue de Luminy, 13009 Marseille, France
Phone Number 33 4 30 30 30 30
Web Address http://www.innate-pharma.com
View Prospectus: Innate Pharma SA
Financial Information
Market Cap $560.3mil
Revenues $143.2 mil (last 12 months)
Net Income $1.3 mil (last 12 months)
IPO Profile
Symbol IPHA
Exchange NASDAQ
Shares (millions): 12.5
Price range $5.50 - $5.50
Est. $ Volume $68.8 mil
Manager / Joint Managers Citigroup/ SVB Leerink/ Evercore ISI
CO-Managers -
Expected To Trade: 10/17/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change